HOUSTON, May 16, 2024
/PRNewswire/ -- Spanios, a firm that created and leverages its
unique 3D tumoroid platforms to validate solid tumor therapies
today announced a partnership with Accelerated Biosciences, a
company that licenses its commercial-grade human trophoblast stem
cell (hTSC) platform for drug discovery, therapeutic development,
biomanufacturing, and toxicology testing.
The partnership combines Spanios' proprietary COMPASS
platforms and patient-derived tumoroid models with AccelBio's hTSC
platform to advance therapeutic design across solid tumor
cancers.
Accelerated Bio's hTSC platform serves as the starting material
for this collaboration. hTSCs are the earliest form of pluripotent
stem cells that are ethically sourced. These cells are highly
plastic and immune-privileged, making them ideal for numerous
medical and biotechnological applications. Among many other
functions that the hTSCs can perform, effector cells derived from
the hTSCs have been shown to be successful against many cancer
cells.
Spanios' tumoroid research expertise enhanced by its ability to
rapidly recapitulate preclinical therapeutic performance ex vivo
will play a key role in generating clinically relevant data for the
hTSCs. "We are excited about the preliminary data supporting the
NK-like behaviors of these cells," said Vivek Ravi, Spanios CEO. "This opens a huge
opportunity for cell-based therapies where other forms have
struggled, especially for Ovarian, Colorectal and other challenging
cancers, and is the driving force for the partnership."
"We are excited to collaborate with Spanios to advance the
research and development of effector cells derived from hTSCs,"
said Yuta Lee, CEO of Accelerated
Bio. "Together, we believe that we can further demonstrate the
versatility of the hTSC platform for the development of the
next-generation precision medicine therapies," said Ravi.
About Accelerated Biosciences
Accelerated Bio represents a transformative approach in the
healthcare sector by leveraging the groundbreaking potential of
hTSCs to revolutionize precision medicine. Originating from an
early and ethical source, the hTSCs possess the extraordinary
ability to perform functions of many cell types with added genetic
stability, natural immune privilege, high expansion capacity, and
ability to manufacture to clinical scale. Accelerated Bio's large,
robust and encumbrance-free intellectual property estate also
ensures Accelerated Bio's and its partners' freedom to innovate.
For more information, please visit www.acceleratedbio.com.
For more information:
Henry Chen
Chief Financial Officer
henry.chen@acceleratedbio.com
acceleratedbio.com
About Spanios
Spanios's proprietary patient-derived 3D tumoroid (PDT)
platforms bring patient diversity and biological complexity of
solid tumors to therapeutic validation as well as to the earliest
stages of drug discovery. The unique platform overcomes the
limitations of traditional approaches such as xenografts and animal
models by creating a resilient replica of host tumor environments
with customizable testing conditions including variable levels of
oxygenation and also immune-complemented. These models encompass
both the tumor and its microenvironment growing together in unison
to develop tumoroids that respond to treatments in a manner similar
to that of the patient. This keeps the focus on identifying new
pathways, bringing optimal treatments to the clinic, by enabling
scientists to fast-track their search for novel cures to bring hope
to millions of patients.
For more information:
Dean P. Remy
Head of Global Commercial Development
deanremy@spanioslab.com
SpaniosLab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerated-biosciences-and-spanios-partner-to-advance-therapeutic-design-across-solid-tumor-cancers-302147243.html
SOURCE Spanios